Choludexan

Selected form

There is no image.

Ursodeoxycholic Acid

Method of action: Bile And Liver Therapy, Cholelitholithic, Choleretic, Gallstone Diluent, Hepatoprotective, Hypocholesterolemic, Immunomodulating, Lipid-Lowering

Treatment option: Alcoholic Liver Disease, Gastritis, Hepatitis, Biliary Bypass, Cholelithiasis, Cystic Fibrosis, Cystic Fibrosis In Children, Nonalcoholic Steatohepatitis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Choludexan

Quick Facts

Property	Description
Active ingredient	Ursodeoxycholic Acid (UDCA)
Form	Capsules or Film-coated tablets, oral administration
Pharmacological class	Bile Acid Medicine, Hepatoprotector
General purpose	To support liver health and modify bile composition
Origin	Synthetically produced secondary bile acid

The Identity of Choludexan: A Bile Acid Medicine and Hepatoprotector

Choludexan is a prescription medicine containing the single active substance Ursodeoxycholic Acid (UDCA), which is classified as a gallstone dissolution agent and a hepatoprotector. The drug's core function is to modify the composition of bile and safeguard the cells of the liver and biliary system.

The compound UDCA is a dihydroxy bile acid. This substance is notably hydrophilic (water-soluble), a quality that distinguishes it from other naturally occurring bile acids that can be more hydrophobic and potentially toxic. Pharmacological data supports the advantage of UDCA, as it is able to displace these more harmful bile acids, thereby maintaining the structural integrity and function of the liver.

Composition and Origin: Is UDCA Natural or Synthetic?

Choludexan is a single-ingredient product available for oral administration in pharmaceutical forms such as capsules and film-coated tablets. While UDCA is chemically a secondary bile acid that exists naturally as a minor fraction in the human body, the compound used in medicine is synthetically produced to ensure consistency and purity.

The medicine is classified as a bile acid derivative and is intended for use in conditions involving impaired bile flow. The drug's singular focus on UDCA provides a targeted therapeutic effect in managing the chemical environment of the liver.

What is the General Purpose of Choludexan?

The general purpose of Choludexan is to support and improve the function of the liver and gallbladder. It achieves this by modifying the chemical composition of bile to make it less saturated with cholesterol, thereby providing an antilithogenic effect.

This systematic action against solid deposit formation, combined with its cellular protection, delivers a corrective benefit to the entire biliary system. UDCA serves as a primary agent for managing liver disorders by promoting bile flow and protecting liver cells.

What side effects are possible with Choludexan?

Possible Side Effects and Safety Information

The safety profile of Choludexan (Ursodeoxycholic Acid) is based on official regulatory classifications, detailing potential adverse reactions and limitations on use. The most frequently observed effects are generally confined to the gastrointestinal system.

Official Adverse Reaction Categories

Adverse reactions are formally classified by frequency in regulatory documents:

Common Reactions (occurring in 1 to 10 out of 100 users): The most frequently reported effects involve the gastrointestinal tract, including loose stools or diarrhoea.
Very Rare Reactions (occurring in less than 1 out of 10,000 users): These effects include severe right upper abdominal pain, calcification of gallstones, and urticaria (allergic rash).

Serious Adverse Reactions and Safety Constraints

A serious adverse reaction documented as very rare is the decompensation of hepatic cirrhosis, which has been observed in patients with advanced Primary Biliary Cholangitis (PBC). This effect is noted to partially reverse upon discontinuation of the medication.

The medicine is subject to specific safety restrictions (contraindications) and should not be used in conditions such as decompensated hepatic cirrhosis, acute inflammation of the gallbladder or biliary tract, and the presence of radio-opaque calcified gall-stones.

Population and Time-Related Safety

Pregnancy: Use is generally not recommended unless clearly necessary, as regulatory data indicates teratogenic effects in animal studies during early gestation.

Time-Related Patterns: In patients being treated for PBC, a worsening of clinical symptoms, such as an increase in pruritus (itching), may be temporarily observed at the beginning of treatment.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information regarding Choludexan (Ursodeoxycholic Acid) overdose focuses on specific documented manifestations and mandated response actions.

Overdose Scope

Feature	Regulatory Documentation Statement
Documented overdose presentations	The primary clinical sign of overdose consistently noted in official labeling is diarrhoea. Other systemic symptoms are deemed unlikely due to the drug’s reduced absorption at high doses.
Physiological systems affected	Primarily the Gastrointestinal system. In patients with advanced liver disease, Hepatobiliary decompensation is a rare, severe outcome noted in official safety profiles.
Dose-related factors	The regulatory profile states that as dose increases, the absorption of the substance decreases, naturally limiting acute systemic toxicity.

Emergency Actions and Classification

Classification	Regulatory Documentation Statement
Severity classification	Acute overdose generally presents with limited systemic toxicity. The most severe outcome is rare decompensation of hepatic cirrhosis.
Emergency-response statement	Treatment for overdose is symptomatic. No specific antidote is known or documented.

Official Overdose Statements

Regulators specify that if diarrhoea occurs, the dose must be reduced, and if the symptom is persistent, therapy should be discontinued.
Urgent medical review is required if monitoring reveals a clinically significant rise in liver function test parameters, as this change may necessitate the immediate discontinuation of the product.
Continuous monitoring of liver function tests (e.g., AST, ALT, gamma-GT) is required to detect early signs of potential hepatotoxicity.

Connection to the Overall Overdose Profile

The regulatory profile defines the overdose risk primarily by the gastrointestinal manifestation of diarrhoea and the absence of a known antidote. Official guidance mandates immediate procedural intervention—dose adjustment or discontinuation—as the essential action when the primary symptom becomes unmanageable or when monitoring indicates the potential for severe, documented hepatobiliary effects.

Therapeutic Uses of Choludexan

What Choludexan Treats: Main Uses and Benefits

Choludexan is generally used across domains where additional symptomatic support is needed. The medicine is applied in scenarios where additional management of discomfort is required. It is considered relevant for conditions associated with acute or disruptive episodes and is also used for managing symptom clusters associated with episodic or fluctuating manifestations.

Support for Conditions Characterized by Heightened Symptoms

The medication is relevant for conditions characterized by periods of heightened symptoms. It helps address symptoms related to systemic imbalance, and its use contributes to easing the overall symptom burden and supports general well-being during symptomatic phases. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Assistance During Phases of Increased Discomfort or Tension

Choludexan is often used during phases when symptoms become more noticeable, providing support that assists with maintaining functional stability when symptoms interfere with daily functioning. Its application is considered relevant when supportive symptom management is appropriate, particularly in contexts marked by increased discomfort or tension.

Quick Fact: Relief for Heightened Symptoms Choludexan is applied in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is needed.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Choludexan

This profile details the officially documented eligibility and non-eligibility rules for the medicine, Ursodeoxycholic Acid, as defined by government regulatory authorities.

Eligibility Scope

Classification	Population Status
Populations Allowed	Adults with Primary Biliary Cholangitis (PBC). Pediatric patients (often ge 6 years) for hepatobiliary disorder associated with cystic fibrosis, where approved.
Use Not Recommended	Patients with decompensated hepatic cirrhosis (e.g., those with ascites or variceal bleeding). Pregnant women, particularly in the first trimester, unless clearly necessary.
Contraindicated Populations	Patients with known hypersensitivity to the active substance, complete biliary obstruction, acute inflammation of the gallbladder or biliary tract, impaired gallbladder contractility, or radio-opaque calcified gallstones.

Eligibility Rules and Restrictions

Age-Related Rules: Use is established for adults. Efficacy and safety are not established for all indications in the pediatric population, but specific use in children with cystic fibrosis-related liver disease is approved in certain regions.
Reproductive Status: Women of childbearing potential are required to use reliable contraception during therapy. Use during breastfeeding is generally not recommended or requires professional consideration to discontinue the drug or nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Choludexan's interaction profile is documented by regulatory authorities across two main domains: substances that counteract its therapeutic efficacy and medicinal products that alter systemic drug exposure.

Contraindicated Combinations and Efficacy Counteraction

Certain medicinal products are formally documented to counteract the action of Choludexan and should not be prescribed concomitantly. Estrogens, including oral contraceptive agents, and lipid-lowering drugs like Clofibrate, increase the secretion of cholesterol into the bile. This action directly opposes the effect of Ursodeoxycholic Acid, rendering it ineffective. To support treatment efficacy, women of childbearing age receiving treatment should utilize non-hormonal or low-oestrogen hormonal contraceptives.

Alteration of Absorption and Plasma Exposure

Several substances reduce the systemic absorption of Choludexan. Bile acid sequestrants (e.g., Cholestyramine) and aluminum-based antacids reduce the quantity of Ursodeoxycholic Acid absorbed. To prevent reduced efficacy, these preparations must be taken at least two hours before or two hours after Choludexan administration. Similarly, charcoal and excessive dietary intake of calories and cholesterol are noted as factors that can reduce treatment effectiveness and should be avoided.

Effects on Other Medicines

Choludexan has been documented to modify the systemic exposure of other co-administered drugs. It increases the absorption and serum concentration of the immunosuppressant Ciclosporin, an effect requiring serum level monitoring and potential dose adjustment for Ciclosporin. Furthermore, Choludexan reduces the plasma exposure (AUC and Cmax) of medicines such as Nitrendipine and Dapsone, an outcome linked to the potential induction of cytochrome P450 3A enzymes.

Mechanism of Action

How Choludexan Works: Mechanism of Action

Bile Acid Pool Substitution and Detoxification

Choludexan's action initiates with Ursodeoxycholic Acid (UDCA) becoming the dominant component of the body's bile acid pool. UDCA, being water-soluble (hydrophilic), physically substitutes the more toxic, fat-soluble bile acids. This displacement mechanism alters the pool's composition, resulting in a bile fluid with diminished detergent properties toward the liver and biliary epithelia.

Cellular Resistance and Flow Enhancement

UDCA integrates into the lipid bilayer of hepatocyte and cholangiocyte cell membranes, a process known as membrane stabilization, which enhances their resistance to chemical injury and modulates pathways that inhibit programmed cell death. Simultaneously, UDCA stimulates bile flow by upregulating key membrane transporters (e.g., AE2 exchanger), promoting the secretion of water and bicarbonate and resulting in an increase in bile volume and flow rate.

Cholesterol Solubilization

This bile acid further exerts its effect by modulating cholesterol metabolism. It acts to decrease the amount of cholesterol secreted by the liver and reduces its absorption from the gut. This dual mechanism directly lowers the saturation of cholesterol in the bile, resulting in the maintenance of cholesterol in a physically soluble state within the fluid medium.

Dosage and Administration Information

Choludexan, which contains ursodeoxycholic acid (UDCA), is typically taken orally in the form of a capsule, tablet, or liquid suspension. The method and dose are highly dependent on the medical condition being treated and the patient's body weight, so it is essential to follow the specific regimen prescribed by a healthcare provider.

General Administration Guidelines

Timing: For most indications, including the dissolution of cholesterol gallstones, the total daily dose is often divided and administered with food to enhance absorption. For gallstone dissolution, a single dose taken at bedtime is frequently recommended. For conditions like Primary Biliary Cholangitis (PBC), the daily dose may initially be split into 2 to 4 doses, which may be consolidated to a once-daily evening dose after the first three months if liver parameters improve.
Tablets/Capsules: Swallow the tablets or capsules whole with water, without chewing them. If using scored tablets that are broken, the segments should be swallowed immediately, as they may have a bitter taste.
Suspension: If using the liquid suspension form, the bottle must be shaken well before measuring each dose using the provided measuring cup or syringe.

Important Considerations

Missed Dose: If a dose is missed, take it as soon as you remember. However, if it is close to the time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not take a double dose to compensate.
Drug Interactions: Avoid taking antacids that contain aluminum salts concurrently, as these may interfere with the absorption of UDCA. A time separation of at least 2 hours between taking Choludexan and such antacids is usually advised.

Recent Clinical Evidence

Evidence for use in Primary Biliary Cholangitis (PBC)

Research on Choludexan (Ursodeoxycholic Acid) for Primary Biliary Cholangitis (PBC) relies on Randomized Controlled Trials, systematic reviews, and long-term observational cohort studies. These studies evaluated the compound in adult patients with compensated disease, monitoring shifts in liver enzyme measurements and tracking major milestones like the postponement of liver transplant need. Findings describe patterns where many patients experienced observed shifts in liver enzyme measurements, and research examined the postponement of liver damage progression (fibrosis and cirrhosis). However, evidence remains limited regarding consistent long-term change in symptoms such as fatigue.

Evidence for Cholesterol Gallstone Dissolution

Choludexan was studied for its role in the dissolution of certain types of gallstones in clinical studies. Research focused on patients with cholesterol-rich gallstones and a functioning gallbladder, specifically monitoring the rate of complete or partial dissolution. Data show patterns related to measured rates of stone dissolution in specific selections of patients, while dissolution rates were described as lower when stones were large or hardened. Follow-up durations were limited, meaning information for long-term outcomes is restricted.

Long-term Research and Sustainability of Findings

Extended observational follow-up constitutes the longest available research on Choludexan for PBC patients. This research explores the sustainability of the initial biochemical changes and the long-term patterns observed in the disease's course. These studies help show what has been observed so far in groups of patients, and findings describe group patterns, not outcomes for an individual.

Research in Specific Patient Groups

Research has explored how this compound was observed in specific patient cohorts, such as patients who experienced recurrence of PBC after a liver transplant. Studies also monitored patients within the main PBC population that were designed to distinguish those who achieved pre-defined biochemical response criteria versus those who were classified as suboptimal or non-responders.

Areas of Research Uncertainty and Gaps

Areas where certainty remains low or evidence is limited include trials for Primary Sclerosing Cholangitis (PSC). These findings were mixed and did not describe a relationship with major clinical endpoints such as overall survival. The persistent question regarding the variability in biochemical response among a subgroup of patients with PBC remains a key focus for researchers.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Choludexan (FAQ)

Q: Does Choludexan treat symptoms or the underlying condition?

The drug's primary action, according to official information, is to modify the composition of bile and safeguard liver cells, which is observed to influence the progression of the underlying condition. Clinical trials indicate that it is associated with improved biochemical markers (substances measured in blood tests), though evidence is limited regarding consistent long-term change in certain symptoms like fatigue.

Q: Is it normal to feel tired after starting Choludexan?

Fatigue is cited in clinical trial data as a known adverse reaction. While the frequency can vary among patients and is dependent on the condition being treated, official product information notes that this effect has been observed in clinical settings.

Q: Do the side effects of Choludexan usually go away over time?

Official product information notes that certain symptoms, such as pruritus (itching), may temporarily worsen when beginning therapy for Primary Biliary Cholangitis (PBC). The most commonly reported side effect, diarrhoea, is described in regulatory sources as requiring dose reduction or discontinuation if the symptom persists.

Q: Is Choludexan meant to be taken for a short period or a long-term treatment?

The duration of treatment depends on the specific condition it is being used for. According to regulatory documents, the treatment for gallstone dissolution typically lasts between 6 months and 2 years, whereas for conditions like Primary Biliary Cholangitis (PBC), it is generally considered a long-term or continuous medication.

Q: Can I stop taking Choludexan suddenly, based on official information?

Official sources indicate that stopping the medication, particularly in patients being treated for progressive liver conditions, is associated with a risk of significant deterioration in liver biochemistry and a worsening of symptoms. A health care provider should guide any changes to the prescribed treatment plan.

Q: What official documents describe the eligibility criteria for Choludexan use?

The approved indications, specific contraindications (reasons not to use the drug), and eligibility rules are formally documented by government regulatory authorities. This information can be found in documents such as the Summary of Product Characteristics (SmPC) in Europe and the FDA Drug Label in the United States.

Q: What kind of general expectations should I have when starting Choludexan?

Clinical studies indicate that treatment is generally associated with an improvement in serum liver parameters (results from certain blood tests). Official product information also notes that patients with PBC may experience a temporary worsening of pruritus (itching) when starting therapy.

Q: Does Choludexan affect fertility in men or women?

Studies reviewed by regulatory agencies have shown no evidence of an adverse effect on fertility in animal models. However, official documents describe a requirement for women of childbearing potential to use a reliable form of non-hormonal contraception, as hormonal contraceptives can counteract the drug’s effectiveness.

Q: Is Choludexan a new medicine or has it been available for a while?

The active ingredient in Choludexan, ursodiol, has been available for several decades. According to the FDA, it received its first approval for gallstone dissolution in 1987 and was subsequently approved for Primary Biliary Cholangitis (PBC).

Q: Can Choludexan cause long-term side effects?

The drug is generally well-tolerated in long-term treatment, and the safety profile lists potential serious adverse reactions based on frequency, which may occur at any time during therapy. One very rare serious reaction observed in patients with advanced PBC is the decompensation of hepatic cirrhosis.

Q: Is weight gain or weight loss a known side effect of Choludexan?

Weight gain has been cited in some clinical trial summaries as an uncommon side effect of the medication. No strong or consistent patterns are noted regarding significant weight loss in official product documents.

Q: Are there any over-the-counter pain relievers that interact with Choludexan?

Regulatory documents specifically warn about reduced absorption of Choludexan if taken concurrently with aluminum-based antacids. Official product information describes the need for time separation for certain medications that interfere with absorption, but no general statement covers all over-the-counter pain relievers.

Q: Does Choludexan have a known interaction with alcohol?

While a direct contraindication is not always listed in regulatory sources, official patient information identifies alcohol use as a factor to be discussed with a healthcare provider.

Q: How quickly does Choludexan typically start to show an effect?

Official studies indicate that the effects on biochemical markers, such as the reduction of elevated liver enzymes, are typically observed after a treatment period of at least one month. Full therapeutic effects may take longer depending on the condition being treated.

Q: What is the expected duration of action of Choludexan?

According to official regulatory data, the concentrations of the drug’s active substance in bile are known to reach a steady-state (a consistent, stable level) in the body in approximately 3 weeks with repeated, consistent dosing.

Q: Is Choludexan considered a first-line treatment according to guidelines?

For Primary Biliary Cholangitis (PBC), the drug is recognized in official guidelines as the established treatment of choice, or standard first-line therapy, supported by multiple clinical trials.

Q: Are there known warnings or precautions about driving or operating machinery while using Choludexan?

Official product documents state that no negative effects on the ability to drive and use machines have been observed in studies of this medication.

Q: Does Choludexan cause dependency or withdrawal symptoms?

The drug is not classified as a controlled substance and is not associated with dependency. However, its withdrawal can lead to a significant deterioration of liver biochemistry and symptoms in patients with progressive disease, highlighting a known risk of sudden cessation.

Q: Is Choludexan a controlled substance in the US or other countries?

Choludexan is classified as a Prescription Only (Rx-only) medicine in the US, UK, Canada, and other regions. It is not listed as a controlled substance by regulatory agencies in these jurisdictions.

Q: Why is it stated in official documents that Choludexan should be discontinued slowly?

Official guidelines describe a need for controlled cessation for several reasons. For conditions like gallstone dissolution, stopping treatment even briefly can prolong the overall duration of therapy. For patients with progressive liver diseases, stopping the drug is associated with a risk of deterioration in liver function, leading to guidelines describing a controlled cessation process.

How should Choludexan be stored and disposed of?

How to Store and Dispose of Choludexan?

The storage and disposal of Choludexan (ursodeoxycholic acid) must adhere to the specific requirements set forth in the official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

The medicine must be stored at a temperature not exceeding 25°C (some formulations specify below 30°C) and should be kept in the original container or carton for protection. This is required to protect the medicine from light and moisture.

It is mandatory that Choludexan be kept out of the sight and reach of children.